Drugs / 90Y-epratuzumab tetraxetan
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01147393 | Oct 2010 → Aug 2013 | follicular lymphoma | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01101581 | May 2010 → Dec 2016 | diffuse large B-cell lymphoma | Gilead Sciences | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT02844530 | ? → Jan 2017 | B-cell acute lymphoblastic leukemia | Nantes University Hospital | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 90Y-Epratuzumab Tetraxetan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01101581 ↗ |
| Route | Intravenous | “90Y-Epratuzumab tetraxetan will be administered intravenously.” NCT01101581 ↗ |
| Target | CD22 | “90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy” NCT01147393 ↗ |